Claims for Patent: 12,109,197

Summary for Patent: 12,109,197

Title:	Combinations of β-lactam compounds and probenecid and uses thereof
Abstract:	The present disclosure relates to combinations of a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a β-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.
Inventor(s):	Michael Dunne
Assignee:	Iterum Therapeutics International Ltd
Application Number:	US18/065,400
Patent Claims:	1. A method of treating or preventing uncomplicated urinary tract infection, comprising: administering to a subject in need thereof from 400 mg to 600 mg of a β-lactam compound or a pharmaceutically acceptable salt thereof, and from 400 mg to 600 mg of probenecid or a pharmaceutically acceptable salt thereof, simultaneously twice daily for from 5 days to 10 days, wherein the β-lactam compound is: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the β-lactam compound or the pharmaceutically acceptable salt thereof, and probenecid or the pharmaceutically acceptable salt thereof, are administered by oral administration. 3. The method of claim 1, wherein an oral co-formulation comprising the β-lactam compound or the pharmaceutically acceptable salt thereof and probenecid or the pharmaceutically acceptable salt thereof is administered. 4. The method of claim 3, wherein a tablet comprising the ß-lactam compound or the pharmaceutically acceptable salt thereof and probenecid or the pharmaceutically acceptable salt thereof is administered. 5. The method of claim 1, wherein a food is administered to the subject during the administration of the β-lactam compound or the pharmaceutically acceptable salt thereof and probenecid or the pharmaceutically acceptable salt thereof. 6. The method of claim 1, wherein the subject in need thereof is a human. 7. The method of claim 1, wherein the β-lactam compound is selected from the group consisting of: or pharmaceutically acceptable salts thereof. 8. The method of claim 1, wherein the β-lactam compound is: or a pharmaceutically acceptable salt thereof. 9. The method of claim 1, wherein the β-lactam compound is: or a pharmaceutically acceptable salt thereof. 10. The method of claim 1, wherein the β-lactam compound or the pharmaceutically acceptable salt thereof, and probenecid or the pharmaceutically acceptable salt thereof, are administered for 5 days.